[Home ] [Archive]   [ فارسی ]  
:: Main :: About :: Current Issue :: Archive :: Search :: Submit :: Contact ::
:: Volume 25, Issue 2 (4-2020) ::
__Armaghane Danesh__ 2020, 25(2): 0-0 Back to browse issues page
Evaluating the efficacy and side effects fingolimod in 3 -year follow-up of patients in RRMS
Masoome Moaref Dr 1, Nazanin Razazian Dr2, Mansour Rezaee Dr3
1- olom pezeshki kermanshah , dr_mmoaref@yahoo.com
2- olom pezeshki ker
3- olom pezeshki kermanshah
Abstract:   (991 Views)
Fingolimod is the first DMT drug to treat MS that oral form was available. This study was done with aim to study the effectiveness and long-term side effects of bio similar fingolimod oral forms in 3-year follow-up of patients with RRMS.
 
 
Methods:
This study was a clinical trial (before and after) on 28 patients with RRMS referring to Clinic of Imam Reza Hospital in Kermanshah. Patients received daily, oral administration of a Fingolimod capsule for at least 36 months. Patients were followed up relapse ,progression disability and Probable complications of drug,every  3-month period  for  36 months after start of fingolimod. EDSS questionnaire for patients in each treatment period was completed.
 
Results:
Information of 28 patients were analyzed and 7 patients(2 drug complications, 1 patient has migrated  and 4 patients had progression disability) were excluded. The mean age was 33.67±7.31 and the mean duration of the disease was 6.89 ± 3.47 years. The mean frequency of recurrence of MS before the intervention was 1.9 ± 1.28 and in the first year after the intervention, it was 0.37 ± 0.68 , In the second year 0.5 ± 0.63 and in the third year it was reduced 0.32 ± 0.47.  88.9% patiens had not progress in  EDSS score. 58.2% of patients did not have new or enlarge T2 lesions. During the 3 years follow-up, the number of lymphocytes and white blood cells in patients was decreasing (P = .0001). The level of liver enzymes ALT and AST was significantly different during the study period (P = 0.0001). Frequency of T2 lesions did not differ before with  after medication intervention fingolimod. However, the frequency of GAD lesions was significantly decreased after intervention (p = 0.003).
Conclusion:
Fingolimod is a good alternative for treatment of RRMS. In addition of  high efficacy and low side effects playing relatively acceptable. Study with larger sample size for evaluation more informed benefits and the dangers of this drug are essential for the relapse of the disease.
Keywords: Fingolimod, Multiple Sclerosis, Complications, Disability
     
Type of Study: Research | Subject: Special
Received: 2019/04/7 | Accepted: 2020/01/19 | Published: 2020/05/4
Send email to the article author

Add your comments about this article
Your username or Email:

CAPTCHA


XML   Persian Abstract   Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

moaref M, razazian N, rezaee M. Evaluating the efficacy and side effects fingolimod in 3 -year follow-up of patients in RRMS. Armaghane danesh. 2020; 25 (2)
URL: http://armaghanj.yums.ac.ir/article-1-2485-en.html


Volume 25, Issue 2 (4-2020) Back to browse issues page
ارمغان دانش Armaghane danesh
Persian site map - English site map - Created in 0.06 seconds with 32 queries by YEKTAWEB 4102